BLATTER Fritz,INGALLINERA Tim,BARF Tjeerd,ARET Edwin,KREJSA Cecile,EVARTS Jerry
申请号：
MDE20180479
公开号：
MD3317281T2
申请日:
2016.07.01
申请国别(地区):
MD
年份:
2020
代理人:
摘要：
In some examples, the invention refers to solid crystalline forms, including polymorphs, hydrates and salt forms, of (S) -4- (8-amino-3- (1- (but-2-inoyl)) pyrrolidine-2-yl) imidazo [1,5-a] pyrazine-l) -N- (pyridine-2-yl) benzamide. In some examples of achievement, the invention refers to,also to pharmaceutical formulations containing solid crystalline forms and methods for treating conditions or disorders by administering a substance of a pharmaceutical formulation including forms, including pharmaceutical formulations and methods to overcome the effects of acid reducing agents. Formula (I)În unele exemple de realizare, invenţia se referă la forme solide cristaline, incluzând polimorfe, hidraţi şi forme de sare, de (S) -4- (8-amino-3- (1 - (but-2-inoil)) pirolidină-2-il ) imidazo [1,5-α] pirazin-l-il) -N- (piridin-2-il) benzamidă. În unele exemple de realizare, invenţia se referă, de asemenea, la compoziţii farmaceutice care conţin forme solide cristaline şi metode pentru tratarea condiţiilor sau tulburărilor prin administrarea unui subiect a unei compoziţii farmaceutice care include formele, inclusiv compoziţii farmaceutice şi metode pentru depăşirea efectelor agenţilor de reducere a acidului . Formula (I)
